University of Calgary Creating Survey to Help Pinpoint Risks of PF

University of Calgary Creating Survey to Help Pinpoint Risks of PF

The University of Calgary is developing a clinical tool to help identify the environmental and occupational risks of pulmonary fibrosis (PF), an undertaking that could lead to a deeper understanding of how the disease takes hold and aid in developing treatments. During the 18-month project, supported by the Three…

Training for Transplant: How I Learned to Breathe Again

Along this journey with idiopathic pulmonary fibrosis, my care team has had several different tools at their disposal. Some must be used in combination with others, while some are only used to gather information. Pulmonary rehabilitation, which can be deployed both pre- and post-transplant, falls under both…

Eucalyptus Compound Found to Reduce Lung Damage in PF Sheep

Pinocembrin, a compound isolated from eucalyptus trees, significantly reduced the signs and symptoms of lung damage in a sheep model of pulmonary fibrosis (PF), a study demonstrated. “We found that pinocembrin improved lung function, attenuated [eased the effect of] lung inflammation, and decreased overall pathology scores compared to damaged…

AstraZeneca, BenevolentAI Identify New Treatment Target

AstraZeneca has added a novel target for idiopathic pulmonary fibrosis (IPF) to its portfolio, which was uncovered using BenevolentAI’s artificial intelligence-driven medication discovery platform. “The cause of IPF is largely unknown and the exact mechanisms involved in the progression of IPF remain elusive,” Anne Phelan, PhD, chief scientific…

Juggling Medications, Lab Tests, and Side Effects After Transplant

My pulmonologists are talented jugglers. They must determine my medication dosages, keep my lab results within the standard ranges, and minimize medication side effects. After my bilateral lung transplant in August 2020, it took a year to find the correct balance between all three. Medication baseline The balancing act started…

Autoantibody Reduction Regimen Improves Lungs, Survival: Study

An autoantibody reduction regimen that combines three treatments improved lung function and survival in adults with idiopathic pulmonary fibrosis (IPF) who are experiencing acute symptom worsening, a small study suggests. Early, positive clinical responses predicted better long-term outcomes, and high levels of autoantibodies against epithelial markers before treatment were…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums